Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

With LAURUSLABS's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.224000
forwardPE 39.599556
debtToEquity 52.143000
earningsGrowth 2.104000
revenueGrowth 0.195000
grossMargins 0.553840
operatingMargins 0.180300
trailingEps 6.620000
forwardEps 23.370000

LAURUSLABS's current ratio of 1.224 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. LAURUSLABS's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
LAURUSLABS's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning LAURUSLABS for continued success in the market.
LAURUSLABS's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that LAURUSLABS's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

Price projections for LAURUSLABS have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for LAURUSLABS's growth and market performance.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


With a recent sell bias for Laurus Labs Limited from analysts, investors should be cautious and consider a variety of market indicators before making decisions. This broader perspective will provide more informed insights into the stock's overall outlook, rather than relying on one analysis alone.